We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ATOS Atossa Therapeutics Inc

0.0305 (4.14%)
Dec 09 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 191,714
Bid Price 0.75
Ask Price 0.79
News -
Day High 0.7669


52 Week Range


Day Low 0.72
Company Name Stock Ticker Symbol Market Type
Atossa Therapeutics Inc ATOS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0305 4.14% 0.7668 00:00:07
Open Price Low Price High Price Close Price Prev Close
0.74 0.72 0.7669 0.7532 0.7363
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,181 191,714 $ 0.7407357 $ 142,009 - 0.50 - 1.39
Last Trade Time Type Quantity Stock Price Currency
19:57:56 10 $ 0.7668 USD

Atossa Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
93.98M 125.30M - 0 -26.96M -0.22 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Atossa Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ATOS Message Board. Create One! See More Posts on ATOS Message Board See More Message Board Posts

Historical ATOS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.73370.770.710.7441518255,0330.03314.51%
1 Month0.65150.8330.620.7262894288,5450.115317.7%
3 Months0.7760.8410.620.7204226322,662-0.0092-1.19%
6 Months0.9771.390.620.9861133589,287-0.2102-21.51%
1 Year0.681.390.500.8797974549,8630.086812.76%
3 Years1.579.800.503.255,483,028-0.8032-51.16%
5 Years1.319.800.503.303,583,779-0.5432-41.47%

Atossa Therapeutics Description

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |